CD8A and cancer: Sharma and colleagues investigated the efficacy of bempegaldesleukin combination with ICI in animal tumor model and noticed the synergizing effects and the benefit of using this IL‐2 prodrug for potentiating the fraction of CD8+ T cells and cancer regression.41